Your browser doesn't support javascript.
loading
The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom
Jia Wei; Nicole Stoesser; Philippa C Matthews; Ruth Studley; Iain Bell; John I Bell; John N Newton; Jeremy Farrar; Ian Diamond; Emma Rourke; Alison Howarth; Brian D Marsden; Sarah Hoosdally; E Yvonne Jones; David I Stuart; Derrick W Crook; Tim EA Peto; Koen B Pouwels; David W Eyre; A Sarah Walker; - COVID-19 Infection Survey team.
Afiliación
  • Jia Wei; University of Oxford
  • Nicole Stoesser; University of Oxford
  • Philippa C Matthews; University of Oxford
  • Ruth Studley; Office for National Statistics, UK
  • Iain Bell; Office for National Statistics, UK
  • John I Bell; University of Oxford
  • John N Newton; Public Health England
  • Jeremy Farrar; Wellcome Trust
  • Ian Diamond; Office for National Statistics, UK
  • Emma Rourke; Office for National Statistics, UK
  • Alison Howarth; University of Oxford
  • Brian D Marsden; University of Oxford
  • Sarah Hoosdally; University of Oxford
  • E Yvonne Jones; University of Oxford
  • David I Stuart; University of Oxford
  • Derrick W Crook; University of Oxford
  • Tim EA Peto; University of Oxford
  • Koen B Pouwels; University of Oxford
  • David W Eyre; University of Oxford
  • A Sarah Walker; University of Oxford
  • - COVID-19 Infection Survey team;
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21255911
ABSTRACT
Real-world data on antibody response post-vaccination in the general population are limited. 45,965 adults in the UKs national COVID-19 Infection Survey receiving Pfizer-BioNTech or Oxford-AstraZeneca vaccines had 111,360 anti-spike IgG measurements. Without prior infection, seroconversion rates and quantitative antibody levels post single dose were lower in older individuals, especially >60y. Two doses achieved high responses across all ages, particularly increasing seroconversion in older people, to similar levels to those achieved after prior infection followed by a single dose. Antibody levels rose more slowly and to lower levels with Oxford-AstraZeneca vs Pfizer-BioNTech, but waned following a single Pfizer-BioNTech dose. Latent class models identified four responder phenotypes older people, males, and those having long-term health conditions were more commonly low responders. Where supplies are limited, vaccines should be prioritised for those not previously infected, and second doses to individuals >60y. Further data on the relationship between vaccine-mediated protection and antibody responses are needed.
Licencia
cc_by
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies Idioma: En Año: 2021 Tipo del documento: Preprint